^
Association details:
| Biomarker: | ERCC2 K751G |
|---|---|
| Cancer: | Osteosarcoma |
| Drug: | cisplatin (DNA synthesis inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients
Excerpt:
Eight single nucleotide polymorphisms in ERCC2, XPC, XPA, ERCC1, ERCC4 and ERCC5 genes were analyzed in 91 patients diagnosed with osteosarcoma and treated with cisplatin….In addition, carrying at least one ERCC2 Lys751GlnG allele was significantly associated with shorter event-free survival (median=184 months, compared with 240 months for TT homozygotes; hazard ratio=5.76, 95% confidence interval=1.30–25.55; P-value=0.021).
DOI:
10.1038/tpj.2009.19
Source:
Title:
Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients
Excerpt:
CONTRADICTING EVIDENCE: Eight single nucleotide polymorphisms in ERCC2, XPC, XPA, ERCC1, ERCC4 and ERCC5 genes were analyzed in 91 patients diagnosed with osteosarcoma and treated with cisplatin….A significant association with tumor response, after correction for multiple testing, was found for the Lys751Gln polymorphism in the ERCC2 gene.
DOI:
10.1038/tpj.2009.19
